Epidemiology of hepatitis E virus infection in a cohort of 4023 immunocompromised patients. (February 2020)

• Record Type: Journal Article
• Authors: Harritshøj, Lene H.; Hother, Christoffer E.; Sengeløv, Henrik; Daugaard, Gedske; Sørensen, Søren S.; Jacobsen, Søren; Perch, Michael; Holm, Dorte K.; Sækmose, Susanne G.; Aagaard, Bitten; Erikstrup, Christian; Hogema, Boris M.; Lundgren, Jens D.; Ullum, Henrik
• Is Part Of: International journal of infectious diseases. Volume 91(2020)
• Page Start: 188
• Page End: 195
• Publication Date: 2020-02
• Subjects: Hepatitis E -- Epidemiology -- Immunocompromised -- Transfusion transmission -- HEV RNA -- Anti-HEV IgG -- Chronic HEV infection; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2019.11.014
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: Hepatitis E virus (HEV) epidemiology was investigated among 4023 immunocompromised patients in Denmark. The prevalence of HEV RNA was 0.15% and ranged between 0.21% and 0.58% among transplantation patients. No evidence of chronic HEV infection or transfusion transmission was detected. The HEV seroprevalence of 22% was not associated with the number of blood transfusions. HEV seroprevalence was not higher among immunocompromised patients than among age- and sex-matched blood donors. Abstract: Objectives: The prevalence of active, chronic, and former hepatitis E virus (HEV) infections was investigated in a cohort of immunocompromised patients. The association with transfusion transmitted HEV was evaluated, and the HEV seroprevalence was compared with that in healthy blood donors. Study design and methods: Serum samples from 4023 immunocompromised patients at Rigshospitalet, Denmark were retrospectively tested for HEV RNA and anti-HEV IgG. HEV RNA-positive patients were followed up by HEV testing, clinical symptoms, and transfusion history. Factors associated with anti-HEV were explored by multivariable logistic regression analysis. Samples from 1226 blood donors were retrospectively tested for anti-HEV IgG. Results: HEV RNA was detected in six patients (0.15%) with no indications of chronic HEV infection. HEV RNA prevalence rates among recipients of allogeneic haematopoietic stem cell transplantation (allo-HSCT) and solid organ transplantation (SOT) were 0.58% and 0.21%, respectively. Transfusion transmitted infections were refuted, and transfusion history was not associated with anti-HEV positivity. The difference in HEV seroprevalence between patients (22.0%) and blood donors (10.9%) decreased when adjusting for age and sex (odds ratio 1.20, 95% confidence interval 0.97–1.48). Conclusions: HEV viremia among allo-HSCT and SOT recipients suggests that clinicians should be aware of this diagnosis. The lack of association of blood transfusion with anti-HEV positivity supports food-borne transmission as the main transmission route of HEV common to both patients and blood donors.